Cartherics Pty Ltd (“Cartherics”) and panCELLa Inc. (“panCELLa”) are pleased to announce their collaboration to research, develop and commercialize products for the treatment of cancer and other debilitating diseases using cell therapy. panCELLa will integrate their exclusive FailSafeTM technology into Cartherics’ proprietary homozygous HLA haplotype cells to bring the power of safe cell therapy to a greater number of patients.
“This technology is an important step to ensure the safety of the next generation of very effective gene-edited stem cell-derived immunotherapies” said Prof. Alan Trounson, CEO Cartherics.
Leveraging the science recently published in “Linking a cell division and a suicide gene to define and improve cell therapy safety” in the November 21st 2018 issue of Nature, panCELLa will maximize the safety level of Cartherics unique therapeutic cancer-killing cells (CAR-T Cells) by building in a molecular kill-switch among the genes of the cells, enabling the efficient elimination of dangerously dividing or rogue cells.
“We anticipate that this partnership will provide for the highest level of cell therapy safety, stated Dr. Andras Nagy, President and CSO of panCELLa. “We are pleased to partner with Cartherics to address the needs of immunotherapy treated cancer patients and to generate FailSafeTM cells for cell therapies in regenerative medicine. It is our mission to provide off-the-shelf universally safe cell therapies for all humankind.”
Cartherics is an Australian private company developing pluripotent stem cell technology and advanced gene editing techniques for the next generation of chimeric antigen receptor technologies (CAR-T). It aims to both improve the efficacy of CAR-T therapy by empowering the CAR-T cell with dual anti-cancer specificities and to develop an off-the-shelf allogeneic treatment that will radically reduce the cost and complexity of CAR-T therapies making them much more accessible to patients with blood and solid cancers.
Key to Cartherics’ CAR-T product design is the use of specific haplotype-induced pluripotent stem cells (iPSC) using forward reprogramming methodologies for inducing immune cell differentiation. Cartherics is currently completing preclinical development in preparation for
undertaking early clinical trials to provide confirming evidence of the safety and effectiveness of its products. Cartherics intends to partner with biotechnology or pharmaceutical companies for late stage development, product registration, and international sales and marketing. The company aims:
• To create a new more effective class of cancer treatments beyond surgery, chemotherapy, biologicals and radiation.
• To develop technologies that supercharge a patient’s immune system, helping it eliminate cancer.
• To develop accessible ‘off-the-shelf’ immunotherapies to fight aggressive forms of cancers like relapsed ovarian and gastric cancers.
About panCELLa Inc.
Incorporated in August 2015, panCELLa ( www.pancella.com ) is an early-stage biotechnology company in Canada’shealthcare sector. panCELLa has created FailSafe™ Induced Allogeneic Cell Tolerance (iACT) Stealth Cells™ and platforms that allow for the development of safe, universal, cost-effective, “off-the-shelf” cell lines. Our mandate is to accelerate cell-based therapies to a broad range of diseases by providing safe therapeutic cell products. We currently assist pharmaceutical and biotechnology companies to achieve this with their own cell lines by offering genome editing services and licensing of our technology.
To view the full press release click here